4-氯-7-乙氧基-6-(1-甲基哌啶-4-基)喹啉-3-羧酸乙酯 | 1024955-27-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 4-氯-7-乙氧基-6-(1-甲基哌啶-4-基)喹啉-3-羧酸乙酯
• 英文名称: ethyl 4-chloro-7-ethoxy-6-(1-methylpiperidin-4-yl)quinoline-3-carboxylate
• CAS: 1024955-27-8
• 化学式: C₂₀H₂₅ClN₂O₃
• 分子量: 376.883
• InChiKey: UWUVCXFGWHEIQP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  51.7
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-氯-7-乙氧基-6-(1-甲基哌啶-4-基)喹啉-3-羧酸乙酯 在 sodium methylate 、 formamide 、 溶剂黄146 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 为溶剂， 生成 4-[(2,4-difluorophenyl)amino]-7-ethoxy-6-(1-methylpiperidin-4-yl)quinoline-3-carboxamide
  参考文献：
  名称：

  Mitigation of cardiovascular toxicity in a series of CSF-1R inhibitors, and the identification of AZD7507

  摘要：

  The potent and selective 3-amido-4-anilinoquinoline CSF-1R inhibitor AZ683 suffered from cardiovascular liabilities, which were linked to the off-target activities of the compound and ion channel activity in particular. Less basic and less lipophilic examples from both the quinoline and cinnoline series demonstrated cleaner secondary pharmacology profiles. Cinnoline 31 retained the required potency and oral PK profile, and was progressed through the safety screening cascade to be nominated into development as AZD7507. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.06.031
• 作为产物：
  描述：

  2-溴-5-硝基苯乙醚 在 platinum(IV) oxide 、 四(三苯基膦)钯 、 氢气 、 potassium carbonate 、 三乙胺 作用下， 以 甲醇 、 N,N-二甲基乙酰胺 、 水 、 乙腈 为溶剂， 40.0~90.0 ℃ 、344.75 kPa 条件下， 生成 4-氯-7-乙氧基-6-(1-甲基哌啶-4-基)喹啉-3-羧酸乙酯
  参考文献：
  名称：

  Mitigation of cardiovascular toxicity in a series of CSF-1R inhibitors, and the identification of AZD7507

  摘要：

  The potent and selective 3-amido-4-anilinoquinoline CSF-1R inhibitor AZ683 suffered from cardiovascular liabilities, which were linked to the off-target activities of the compound and ion channel activity in particular. Less basic and less lipophilic examples from both the quinoline and cinnoline series demonstrated cleaner secondary pharmacology profiles. Cinnoline 31 retained the required potency and oral PK profile, and was progressed through the safety screening cascade to be nominated into development as AZD7507. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.06.031

文献信息

• CHEMICAL COMPOUNDS
  申请人：Dakin Leslie

  公开号：US20090270450A1

  公开（公告）日：2009-10-29

  The invention relates to chemical compounds of formula (I): or pharmaceutically acceptable salts thereof which possess CSF-1R kinase inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.

  该发明涉及化学式（I）的化合物或其药学上可接受的盐，其具有CSF-1R激酶抑制活性，因此在抗癌活性方面有用，因此可以用于人或动物体的治疗方法。该发明还涉及制造所述化学化合物的过程，含有它们的制药组合物以及它们在制造用于在温血动物（例如人）中产生抗癌效果的药物中的使用。
• WO2008/56148
  申请人：——

  公开号：——

  公开（公告）日：——
• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSÉS CHIMIQUES
  申请人：ASTRAZENECA AB

  公开号：WO2008056148A1

  公开（公告）日：2008-05-15

  [EN] The invention relates to chemical compounds of formula (I): or pharmaceutically acceptable salts thereof which possess CSF 1R kinase inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti cancer effect in a warm blooded animal such as man.
  [FR] L'invention porte sur des composés chimiques de formule (I) ou sur des sels pharmaceutiquement acceptables de ceux-ci possédant une activité inhibitrice de la CSF 1R kinase et en conséquence utiles contre le cancer et donc dans des procédés de traitement du corps humain ou animal. L'invention porte également sur des procédés de fabrication desdits composés chimiques, sur des compositions pharmaceutiques les contenant et sur leur utilisation dans la fabrication de médicaments utilisés pour leur effet anti-cancer chez un animal à sang chaud tel que l'homme.